X0306 4 2014-01-02 1 0001172480 SANTARUS INC SNTS 0001024004 HALE DAVID F C/O SANTARUS, INC. 3611 VALLEY CENTRE DRIVE #400 SAN DIEGO CA 92130 1 0 0 0 Common Stock 2014-01-02 4 U 0 130739 32.00 D 0 I By Family Trust Common Stock 2014-01-02 4 U 0 164713 32.00 D 0 I By Hale BioPharma Ventures LLC Common Stock 2014-01-02 4 U 0 5000 32.00 D 0 I By Family Limited Partnership Common Stock 2014-01-02 4 U 0 18000 32.00 D 0 D Stock Options (right to buy) 21.93 2014-01-02 4 D 0 42000 10.07 D 2023-06-11 Common Stock 42000 0 I By Family Trust Stock Options (right to buy) 6.73 2014-01-02 4 D 0 42000 25.27 D 2022-06-13 Common Stock 42000 0 I By Family Trust Stock Options (right to buy) 3.12 2014-01-02 4 D 0 42000 28.88 D 2021-06-15 Common Stock 42000 0 I By Family Trust Stock Options (right to buy) 3.33 2014-01-02 4 D 0 32000 28.67 D 2021-03-10 Common Stock 32000 0 I By Family Trust Stock Options (right to buy) 5.32 2014-01-02 4 D 0 42000 26.68 D 2017-06-14 Common Stock 42000 0 I By Family Trust Stock Options (right to buy) 6.73 2014-01-02 4 D 0 40000 25.27 D 2016-06-07 Common Stock 40000 0 I By Family Trust Stock Options (right to buy) 3.00 2014-01-02 4 D 0 25000 29.00 D 2015-06-09 Common Stock 25000 0 I By Family Trust Stock Options (right to buy) 10.00 2014-01-02 4 D 0 25000 22.00 D 2014-07-27 Common Stock 25000 0 I By Family Trust Stock Options (right to buy) 9.00 2014-01-02 4 D 0 25000 23.00 D 2014-04-01 Common Stock 25000 0 I By Family Trust Stock Options (right to buy) 9.45 2014-01-02 4 D 0 10000 22.55 D 2014-02-26 Common Stock 10000 0 I By Family Trust By Hale Family Trust dated February 10, 1986. The reporting person is Chairman. By the Hale Trading Company, L.P. Represents options to purchase common stock of Santarus, Inc. ("Santarus"). In connection with the merger (the "Merger") of Willow Acquisition Sub Corporation ("Merger Sub") with and into Santarus pursuant to the Agreement and Plan of Merger, dated as of November 7, 2013 (the "Merger Agreement"), between Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., Merger Sub and Santarus, such options (i) became fully vested and exercisable prior to the effective time of the Merger and (ii) to the extent not exercised on or prior to the effective time, were cancelled and converted into the right to receive a cash payment in the amount by which the per share purchase price of $32.00 exceeded the exercise price of the option as of the effective time of the Merger. /s/ Carey J. Fox Attorney-in-fact 2014-01-06